- Precision BioSciences Inc DTIL has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)
- PBCAR19B is an immune-evading allogeneic CAR T stealth cell candidate.
- The study's primary objective is to identify the maximum tolerated dose and any dose-limiting toxicities.
- Price Action: DTIL shares are down 0.16% at $12.50 during the market session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
